ARTICLE | Company News
The companies partnered to develop Merck’s M1095 (ALX-0761) to treat plaque psoriasis. Avillion will be responsible for developing the candidate through Phase III testing and will also finance development through to a regulatory submission. Phase II testing is slated to start this year. The partners declined to disclose financial terms...